vs
Side-by-side financial comparison of COLLEGIUM PHARMACEUTICAL, INC (COLL) and LiveRamp Holdings, Inc. (RAMP). Click either name above to swap in a different company.
LiveRamp Holdings, Inc. is the larger business by last-quarter revenue ($212.2M vs $205.4M, roughly 1.0× COLLEGIUM PHARMACEUTICAL, INC). LiveRamp Holdings, Inc. runs the higher net margin — 18.8% vs 8.3%, a 10.5% gap on every dollar of revenue. On growth, COLLEGIUM PHARMACEUTICAL, INC posted the faster year-over-year revenue change (12.9% vs 8.6%). Over the past eight quarters, COLLEGIUM PHARMACEUTICAL, INC's revenue compounded faster (19.1% CAGR vs 11.1%).
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative, abuse-deterrent pain management therapies. Operating primarily in the U.S. market, it offers extended-release analgesics for chronic pain patients, serving providers across primary and specialty care segments.
LiveRamp Holdings, Inc., is an American SaaS company that offers a data connectivity platform whose services include data onboarding, the transfer of offline data online for marketing purposes.
COLL vs RAMP — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $205.4M | $212.2M |
| Net Profit | $17.0M | $39.9M |
| Gross Margin | 62.5% | 71.9% |
| Operating Margin | 29.6% | 18.6% |
| Net Margin | 8.3% | 18.8% |
| Revenue YoY | 12.9% | 8.6% |
| Net Profit YoY | 35.3% | 255.7% |
| EPS (diluted) | $0.48 | $0.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $205.4M | $212.2M | ||
| Q3 25 | $209.4M | $199.8M | ||
| Q2 25 | $188.0M | $194.8M | ||
| Q1 25 | $177.8M | $188.7M | ||
| Q4 24 | $181.9M | $195.4M | ||
| Q3 24 | $159.3M | $185.5M | ||
| Q2 24 | $145.3M | $176.0M | ||
| Q1 24 | $144.9M | $171.9M |
| Q4 25 | $17.0M | $39.9M | ||
| Q3 25 | $31.5M | $27.4M | ||
| Q2 25 | $12.0M | $7.7M | ||
| Q1 25 | $2.4M | $-6.3M | ||
| Q4 24 | $12.5M | $11.2M | ||
| Q3 24 | $9.3M | $1.7M | ||
| Q2 24 | $19.6M | $-7.5M | ||
| Q1 24 | $27.7M | $-5.4M |
| Q4 25 | 62.5% | 71.9% | ||
| Q3 25 | 61.7% | 70.2% | ||
| Q2 25 | 57.7% | 70.1% | ||
| Q1 25 | 54.8% | 69.3% | ||
| Q4 24 | 54.0% | 71.9% | ||
| Q3 24 | 60.8% | 72.4% | ||
| Q2 24 | 62.5% | 70.6% | ||
| Q1 24 | 63.1% | 72.2% |
| Q4 25 | 29.6% | 18.6% | ||
| Q3 25 | 29.7% | 10.7% | ||
| Q2 25 | 18.7% | 3.7% | ||
| Q1 25 | 12.2% | -6.1% | ||
| Q4 24 | 20.9% | 7.5% | ||
| Q3 24 | 21.9% | 4.0% | ||
| Q2 24 | 32.7% | -3.0% | ||
| Q1 24 | 34.1% | -8.3% |
| Q4 25 | 8.3% | 18.8% | ||
| Q3 25 | 15.0% | 13.7% | ||
| Q2 25 | 6.4% | 4.0% | ||
| Q1 25 | 1.4% | -3.3% | ||
| Q4 24 | 6.9% | 5.7% | ||
| Q3 24 | 5.9% | 0.9% | ||
| Q2 24 | 13.5% | -4.3% | ||
| Q1 24 | 19.1% | -3.1% |
| Q4 25 | $0.48 | $0.62 | ||
| Q3 25 | $0.84 | $0.42 | ||
| Q2 25 | $0.34 | $0.12 | ||
| Q1 25 | $0.07 | $-0.10 | ||
| Q4 24 | $0.36 | $0.17 | ||
| Q3 24 | $0.27 | $0.03 | ||
| Q2 24 | $0.52 | $-0.11 | ||
| Q1 24 | $0.71 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $386.7M | $403.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $301.7M | $962.3M |
| Total Assets | $1.7B | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $386.7M | $403.4M | ||
| Q3 25 | $285.9M | $376.9M | ||
| Q2 25 | $222.2M | $371.1M | ||
| Q1 25 | $197.8M | $420.8M | ||
| Q4 24 | $162.8M | $384.3M | ||
| Q3 24 | $120.0M | $348.4M | ||
| Q2 24 | $271.6M | $342.7M | ||
| Q1 24 | $318.0M | $368.9M |
| Q4 25 | $301.7M | $962.3M | ||
| Q3 25 | $274.8M | $943.8M | ||
| Q2 25 | $232.2M | $947.8M | ||
| Q1 25 | $234.4M | $948.9M | ||
| Q4 24 | $228.8M | $957.7M | ||
| Q3 24 | $234.3M | $932.1M | ||
| Q2 24 | $216.6M | $951.9M | ||
| Q1 24 | $222.2M | $949.1M |
| Q4 25 | $1.7B | $1.3B | ||
| Q3 25 | $1.6B | $1.2B | ||
| Q2 25 | $1.6B | $1.2B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.7B | $1.3B | ||
| Q3 24 | $1.6B | $1.2B | ||
| Q2 24 | $1.1B | $1.2B | ||
| Q1 24 | $1.1B | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $123.0M | — |
| Free Cash FlowOCF − Capex | $122.4M | — |
| FCF MarginFCF / Revenue | 59.6% | — |
| Capex IntensityCapex / Revenue | 0.3% | 0.1% |
| Cash ConversionOCF / Net Profit | 7.25× | — |
| TTM Free Cash FlowTrailing 4 quarters | $327.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $123.0M | — | ||
| Q3 25 | $78.4M | $57.4M | ||
| Q2 25 | $72.4M | $-15.8M | ||
| Q1 25 | $55.4M | — | ||
| Q4 24 | $84.6M | $45.1M | ||
| Q3 24 | $-9.0M | $55.6M | ||
| Q2 24 | $67.4M | $-9.3M | ||
| Q1 24 | $61.9M | — |
| Q4 25 | $122.4M | — | ||
| Q3 25 | $78.3M | $56.8M | ||
| Q2 25 | $72.4M | $-16.2M | ||
| Q1 25 | $54.6M | — | ||
| Q4 24 | $84.1M | $44.8M | ||
| Q3 24 | $-9.2M | $55.4M | ||
| Q2 24 | $67.1M | $-9.6M | ||
| Q1 24 | $61.4M | — |
| Q4 25 | 59.6% | — | ||
| Q3 25 | 37.4% | 28.4% | ||
| Q2 25 | 38.5% | -8.3% | ||
| Q1 25 | 30.7% | — | ||
| Q4 24 | 46.2% | 22.9% | ||
| Q3 24 | -5.8% | 29.8% | ||
| Q2 24 | 46.2% | -5.4% | ||
| Q1 24 | 42.3% | — |
| Q4 25 | 0.3% | 0.1% | ||
| Q3 25 | 0.1% | 0.3% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | 0.4% | 0.2% | ||
| Q4 24 | 0.3% | 0.1% | ||
| Q3 24 | 0.2% | 0.1% | ||
| Q2 24 | 0.2% | 0.1% | ||
| Q1 24 | 0.4% | 1.0% |
| Q4 25 | 7.25× | — | ||
| Q3 25 | 2.49× | 2.09× | ||
| Q2 25 | 6.05× | -2.04× | ||
| Q1 25 | 22.92× | — | ||
| Q4 24 | 6.75× | 4.02× | ||
| Q3 24 | -0.96× | 32.10× | ||
| Q2 24 | 3.44× | — | ||
| Q1 24 | 2.23× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
